[go: up one dir, main page]

PE20060378A1 - Regimenes y kits de progestina ciclica - Google Patents

Regimenes y kits de progestina ciclica

Info

Publication number
PE20060378A1
PE20060378A1 PE2005000783A PE2005000783A PE20060378A1 PE 20060378 A1 PE20060378 A1 PE 20060378A1 PE 2005000783 A PE2005000783 A PE 2005000783A PE 2005000783 A PE2005000783 A PE 2005000783A PE 20060378 A1 PE20060378 A1 PE 20060378A1
Authority
PE
Peru
Prior art keywords
progestin
regimes
kits
cyclic
administration
Prior art date
Application number
PE2005000783A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35064935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060378(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060378A1 publication Critical patent/PE20060378A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN REGIMEN DE ADMINISTRACION QUE COMPRENDE: A) UNA PRIMERA FASE DE ADMINISTRACION DE 21-27 UNIDADES DE DOSIFICACION DIARIA CONTENIENDO UNA PROGESTINA SELECCIONADA ENTRE 17-HIDROXIPROGESTERONA, ESTERES DE 19-NOR-TESTOSTERONA, NORETINDRONA, DIDROGESTERONA, TANAPROGET, ENTRE OTROS; B) UNA SEGUNDA FASE DE ADMINISTRACION QUE COMPRENDE 1-7 DIAS DE UN PLACEBO. REFERIDA TAMBIEN A UN KIT DE ADMINISTRACION ORAL O DE LIBERACION PROLONGADA TAL COMO TRANSDERMICO, TRANSMUCOSAL O TRANSVAGINAL UTILES PARA LA ANTICONCEPCION
PE2005000783A 2004-07-07 2005-07-06 Regimenes y kits de progestina ciclica PE20060378A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58604504P 2004-07-07 2004-07-07

Publications (1)

Publication Number Publication Date
PE20060378A1 true PE20060378A1 (es) 2006-06-02

Family

ID=35064935

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000783A PE20060378A1 (es) 2004-07-07 2005-07-06 Regimenes y kits de progestina ciclica

Country Status (14)

Country Link
US (3) US20060009428A1 (es)
EP (1) EP1773344A1 (es)
JP (2) JP5288796B2 (es)
CN (2) CN1980676A (es)
AR (1) AR049707A1 (es)
AU (1) AU2005269938A1 (es)
BR (1) BRPI0512991A (es)
CA (1) CA2571377C (es)
MX (1) MXPA06014579A (es)
PA (1) PA8638601A1 (es)
PE (1) PE20060378A1 (es)
SV (1) SV2006002165A (es)
TW (1) TW200603813A (es)
WO (1) WO2006014476A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AU2005269938A1 (en) 2004-07-07 2006-02-09 Wyeth Cyclic progestin regimens and kits
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ATE460937T1 (de) * 2005-04-28 2010-04-15 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
ES2327783T3 (es) 2005-04-28 2009-11-03 Wyeth Composiciones que contienen tanaproget micronizado.
DE602006013114D1 (de) * 2005-04-28 2010-05-06 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
BRPI0611250A2 (pt) 2005-06-09 2011-02-15 Wyeth Corp composto, enanciÈmeros, diastereoisÈmeros do mesmo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
US20090170823A1 (en) * 2007-12-20 2009-07-02 Duramed Pharmaceuticals, Inc. Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
CA2740002C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
BR112012019725A2 (pt) * 2010-02-08 2020-11-10 Tao Tom Du usos de uma composição farmacêutica e uso de pelo menos um progestogênio
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
MY187233A (en) * 2015-06-23 2021-09-13 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN107982520A (zh) * 2017-12-25 2018-05-04 上海交通大学医学院附属第九人民医院 外源性MPA与hMG在制备动物模型药物中的应用
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception
WO2024218800A1 (en) * 2023-04-21 2024-10-24 Akums Drugs And Pharmaceuticals Limited Vaginal drug delivery system of dydrogesterone

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
ATE209919T1 (de) * 1987-09-24 2001-12-15 Jencap Res Ltd Oestrogen und progestin enthaltende verhütungspackungen
BR9710566A (pt) 1996-07-26 1999-08-17 American Home Prod M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
WO2001030355A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
AU4134599A (en) * 1998-04-07 1999-10-25 Akzo Nobel N.V. Progestogen-only contraceptive kit
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
EP1175411B1 (en) * 1999-05-04 2008-02-20 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
SI20853A (sl) * 1999-08-31 2002-10-31 Jenapharm Gmbh & Co. Kg Mezoprogestini (modulatorji receptorja progesterona) kot sestavina ženskih kontraceptivov
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1665510A (zh) * 2002-06-25 2005-09-07 惠氏公司 作为pr调节剂的环硫代氨基甲酸酯衍生物的衍生物和其用于治疗皮肤病的用途
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
AU2005269938A1 (en) 2004-07-07 2006-02-09 Wyeth Cyclic progestin regimens and kits
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
US8604027B2 (en) 2013-12-10
CA2571377A1 (en) 2006-02-09
US20140094458A1 (en) 2014-04-03
TW200603813A (en) 2006-02-01
US20060009428A1 (en) 2006-01-12
JP2013040181A (ja) 2013-02-28
BRPI0512991A (pt) 2008-04-22
AR049707A1 (es) 2006-08-30
US20100292198A1 (en) 2010-11-18
AU2005269938A1 (en) 2006-02-09
MXPA06014579A (es) 2007-03-01
PA8638601A1 (es) 2006-07-03
CN104208067A (zh) 2014-12-17
JP2008505909A (ja) 2008-02-28
JP5288796B2 (ja) 2013-09-11
SV2006002165A (es) 2006-05-09
CN1980676A (zh) 2007-06-13
WO2006014476A1 (en) 2006-02-09
CA2571377C (en) 2014-03-25
EP1773344A1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
PE20060378A1 (es) Regimenes y kits de progestina ciclica
DK1768625T3 (da) Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
MX391854B (es) Formulaciones farmaceuticas que contienen hidrato de propilenglicol de dapagliflozina
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
AR058175A1 (es) Composiciones farmaceuticas solidas que contienen pregabalina
BR112012018670A2 (pt) combinação, uso de um composto, composição farmacêutica, e, pacote de paciente
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
DK2114383T3 (da) Små-volumen orale transmukosale doseringsformer indeholdende sufentanil til behandling af smerte
GT200900023A (es) Formas farmacéuticas de dosificación oral que contienen un analgésico opioide.
PE20060485A1 (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
CY1115064T1 (el) Διαδερμικο συστημα παραδοσης ορμονων χωρις ενισχυτες διεισδυσης
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
ATE538790T1 (de) Scopolamin für die behandlung von depression und ängstlichkeit
PE20081895A1 (es) Regimen anticonceptivo oral
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal